EUCTR2011-001290-78-GB进行中（未招募）1 期
Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma - MAPPING
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Females older than 18 years; (no upper limit).
- •2.Patients with histologically confirmed cancer of the cervix or endometrium.
- •a.In patient with cervix cancer, there must be confirmation of invasive disease; FIGO stage 1B1 or higher FIGO stage demonstrated clinically and/or on MRI. In patients with advanced disease being considered for chemoradiotherapy treatment, patients may be considered for entry if nodal lymphadenectomy is being used to inform radiotherapy planning;
- •b.In patients with endometrial cancer, a) stage 1A with myometrial invasion or any higher stage and grade 3 histology with lymphovascular space invasion, b) stage 1A with myometrial invasion or any other higher stage and mixed mullerian, serous papillary or clear cell sub-types.
- •c.Stage II disease or above and any histology grade
- •The MDT decision may be based on the combination of tumour characteristics on histology, clinical and imaging findings.
- •3.No contra-indication to FDG-PET/CT, FEC-PET/CT or MRI.
- •4.Fit for surgical lymphadenectomy, as determined by the local MDT. The patient should also be considered fit for extended field radiotherapy in cases where lymphadenectomy is being undertaken to inform radiotherapy planning.
- •5.Able and willing to give written informed consent and to comply with the study protocol procedures
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 100
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •1.Known contra-indication to MRI or PET/CT scan.
- •2.Known allergy to FDG or FEC.
- •3.Not considered fit for lymphadenectomy (open or laparoscopic) or, where appropriate, radiotherapy, as determined by the local MDT.
- •4.If the patient is pregnant or breast-feeding.
- •5.Females of childbearing potential must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 6 weeks after the last PET/CT scan.
- •5.Note: subjects are not considered of childbearing potential if they are surgically sterile (they have undergone bilateral tubal ligation or bilateral oophorectomy) or they are postmenopausal
- •6.Females of childbearing potential must have a negative pregnancy test prior to being registered for the study.
- •7.Medical or psychiatric illness, which makes the patient unsuitable or unable to give informed consent.
研究者
相似试验
招募中
不适用
Combined diffusion tensor imaging (DTI, global fiber tracking and voxel based morphometry (VBM) in patients with idiopathic or atypical Parkinson syndromeG20G23Parkinson diseaseOther degenerative diseases of basal gangliaDRKS00003454eurologische Universitätsklinikum Freiburg200
已完成
不适用
Inverse Probability of Treatment Weighting Analysis of Upfront Surgery versus Neoadjuvant Chemoradiotherapy followed by Surgery for Pancreatic Adenocarcinoma with Arterial AbutmentPancreatic adenocarcinoma (PDAC) which were deemed borderline resectable through preoperative imaging due to abutment of the major artery, including the superior mesenteric artery (SMA) or common hepatic artery (CHA).JPRN-UMIN000017115Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine92
进行中（未招募）
不适用
Vaginal ring dysmenorrhea feasibility trial.This study will investigate the use of 4 doses of combined contraceptives (a progestin with an estrogen) in a vaginal ring dosage form for the treatment of dysmenorrhea (menstrual cramping pain). A placebo control arm will also be utilized.MedDRA version: 14.1Level: LLTClassification code 10013934Term: DysmenorrheaSystem Organ Class: 100000004872EUCTR2012-002449-40-PLMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.450
进行中（未招募）
不适用
Vaginal ring dysmenorrhea feasibility trial.EUCTR2012-002449-40-SEMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.450
进行中（未招募）
1 期
Vaginal ring dysmenorrhea feasibility trial.This study will investigate the use of 4 doses of combined contraceptives (a progestin with an estrogen) in a vaginal ring dosage form for the treatment of dysmenorrhea (menstrual cramping pain). A placebo control arm will also be utilized.MedDRA version: 15.0 Level: LLT Classification code 10013934 Term: Dysmenorrhea System Organ Class: 10038604 - Reproductive system and breast disordersEUCTR2012-002449-40-NOMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.439